Treatment Of Patients With Social Anxiety Disorder

• Status: Completed
• Trial end date: 2007-09-05
• Target enrollment: 0
• Participant gender: All

Summary

GW876008 is a drug which may change mans reaction to stress, by decreasing the fear, physical and behavior symptoms that people with SocAD experience in social situations.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Paroxetine

Criteria

Inclusion criteria:

• are diagnosed with generalized social anxiety disorder/social phobia.

Exclusion criteria:

• have a diagnosis of major depressive disorder

• have a history of Schizophrenia, Schizoaffective Disorder, or Bipolar Disorder.